On Sept 28, 2020, the US Food and Drug Administration (FDA) approved Pfizer’s targeted synthetic drug tofacitinib (Xeljanz) for the treatment of polyarticular juvenile idiopathic arthritis. The drug, a Janus kinase (JAK) inhibitor, had previously been approved for use in adults with rheumatoid arthritis, but is the first in its class to be approved to treat children, providing another weapon in the fight against a complex chronic condition. Read more in The Lancet Rheumatology.